Druggability & Clinical Context
Druggability
Low
Score: 0.35
Druggability Analysis
Structural Tractability0.70
Key Metrics
PDB Structures:
7
Known Drugs:
1
Approved:
0
In Clinical Trials:
0
Drug Pipeline (1 compounds)
1 Preclinical
Druggability Rationale: AQP4 presents moderate-to-low druggability challenges despite being a well-characterized channel with multiple crystal structures (7 PDB entries at 1.8 Å resolution). The low druggability score (0.30) reflects difficulties in targeting water channel selectivity and achieving sufficient potency with small molecules; however, the existence of preclinical lead TGN-020 and availability of cryo-EM and AlphaFold structures provide a structural foundation for rational drug design targeting brain edema and neuroinflammatory conditions.
Mechanism: Water channel inhibitor or modulator
Drug Pipeline (1 compounds)
1 Preclinical
Known Drugs:TGN-020 (preclinical) — Brain edema
Structural Data:PDB (7) ✓AlphaFold ✓Cryo-EM ✓
Selectivity & Safety Considerations
AQP4 selectivity is complicated by the existence of 13 aquaporin isoforms with varying tissue distribution; achieving CNS-specific inhibition while avoiding off-target effects on peripheral aquaporins (particularly AQP1, AQP3) is a major challenge. The astrocyte-specific localization of AQP4 provides a potential selectivity advantage for CNS-directed therapeutics.